logo-loader

Summit Therapeutics welcomes investment from US billionaire ahead of busy Q1

Published: 02:57 15 Jan 2019 AEDT

Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM), discusses with Proactive London's Andrew Scott the recent US$25mln investment in the company by US healthcare entrepreneur Robert Duggan.

Duggan was the chief executive and chairman of Pharmacyclics before it was sold to pharma giant AbbVie Inc (NYSE:ABBV) for US$21bn in 2015.

The purchase will take Duggan’s stake, which sat at just 0.2% before, to 48.8%.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 31 minutes ago